# STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

> **NCT07280585** · PHASE3 · RECRUITING · sponsor: **University of Cologne** · enrollment: 420 (estimated)

## Conditions studied

- Polycystic Kidney, Autosomal Dominant

## Interventions

- **DRUG:** Dapagliflozin 10 mg
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT07280585
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-16
- **Primary completion:** 2030-05-15
- **Final completion:** 2030-05-15
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07280585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07280585, "STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07280585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*